Nextplat Corp (NXPL) - Q1 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2025. Nextplat Corp operates two primary segments: e-Commerce Operations (satellite communication services and equipment sales via platforms like Amazon and Alibaba) and Healthcare Operations (pharmacy services, 340B contract administration, and data management). The company is a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Net Revenue | $14.5 million | $17.5 million |
| Gross Profit | $3.5 million | $4.9 million |
| Gross Margin | 23.8% | 27.8% |
| Net Loss (Attributable to Nextplat) | $(1.3) million | $(1.5) million |
| Loss Per Share (Basic & Diluted) | $(0.05) | $(0.08) |
| Cash and Equivalents | $17.7 million | $23.5 million (End of Q1 2024) |
| Working Capital | $22.1 million | N/A |
| Total Debt (Notes Payable) | $1.3 million | $1.4 million |
| Operating Cash Flow | $(2.1) million | $(2.7) million |
Material Changes vs. Prior Period
- Revenue Decline: Net revenue decreased by 17% ($3.0 million) year-over-year. This was driven primarily by a $3.1 million decrease in Healthcare Operations, partially offset by a $0.1 million increase in e-Commerce.
- Healthcare Segment Pressure: Pharmacy 340B contract revenue dropped 57% ($1.9 million) due to clients transitioning to other partners or opening in-house pharmacies. Prescription volume fell from 134,000 to 107,000 fills.
- Expense Reduction: Total operating expenses decreased 26% ($1.8 million). Significant drivers included a $0.7 million drop in intangible asset amortization (due to prior year impairments) and a $0.6 million reduction in salaries/wages (due to the vesting of non-recurring stock grants).
- Margin Compression: Gross margins declined from 27.8% to 23.8%, attributed to lower-margin 340B contract revenue mix and new airtime costs in the e-Commerce segment following a contract expiration.
Outlook, Risks, and Management Commentary
- Liquidity: Management states cash resources ($17.7 million) are sufficient to support operations for the next 12 months. Cost reduction measures are underway to improve efficiency.
- Strategic Alternatives: Management is exploring options including the sale or merger of portions of the business and strategic joint ventures to diversify operations.
- Tariff Risks: U.S. and Chinese tariffs are a material risk. While Q1 2025 was not materially impacted, Q2 2025 may see adverse effects on costs. The company has paused certain initiatives in its China e-Commerce development program (e.g., Florida Sunshine vitamins) due to tariff exposure.
- Internal Controls: The company disclosed a material weakness in internal controls related to inventory valuation discovered in fiscal 2024. Remediation efforts are ongoing and expected to be validated by the end of Q2 2025.
- Legal Proceedings: The company is defending against a putative class action suit regarding the 2024 merger with Progressive Care (RXMD) and an EEOC claim from a former employee. No accruals have been recorded as outcomes are uncertain.
Investor Verification Checklist
- Verify the sustainability of the 57% decline in 340B contract revenue and the timeline for replacing lost clients.
- Assess the impact of U.S./China tariffs on the e-Commerce segment's Q2 and Q3 2025 margins.
- Monitor the remediation progress of the material weakness regarding inventory valuation controls.
- Review the status of the Weisberg class action lawsuit regarding the RXMD merger consideration.
- Confirm the timeline and potential value of the strategic alternatives (sale/merger) currently under exploration.